New developments in oral contraception: clinical utility of estradiol valerate/dienogest (Natazia^®) for contraception and for treatment of heavy menstrual bleeding: patient considerations

References

• Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 versus > 20 jag estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2011;1:CD003989.
   Google Scholar
• Fruzzetti F, Bitzer J. Review of clinical experience with estradiol in combined oral contraceptives. Contraception. 2010;81(1):8–15.
   PubMed Web of Science ®Google Scholar
• Dhont M. History of oral contraception. Eur J Contracept Reprod Health Care. 2010c;15 Suppl 2:S12–S18.
   Google Scholar
• World Health Organization Task Force on Oral Contraception. A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens. Contraception. 1980;21(5):445–459.
   PubMed Web of Science ®Google Scholar
• Serup J, Bostofte E, Larsen S, Westergaard J. Effectivity and acceptability of oral contraceptives containing natural and artificial estrogens in combination with a gestagen. A controlled double-blind investigation. Acta Obstet Gynecol Scand. 1981;60(2):203–206.
   Web of Science ®Google Scholar
• Serup J, Bostofte E, Larsen S, Westergaard J, Lebech PE. Natural oestrogens for oral contraception. Lancet. 1 1979;2(8140):471–472.
   Web of Science ®Google Scholar
• Schubert W, Cullberg G. Ovulation inhibition with 17 beta-estradiol cyclo-octyl acetate and desogestrel. Acta Obstet Gynecol Scand. 1987;66(6):543–547.
   Web of Science ®Google Scholar
• Csemiczky G, Dieben T, Coeling Bennink HJ, Landgren BM. The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17 beta-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desogestrel only for 7 days. Contraception. 1996;54(6):333–338.
   Web of Science ®Google Scholar
• Borgelt LM, Martell CW Estradiol valerate/dienogest: a novel combined oral contraceptive. Clin Ther. 2012;34(1):37–55.
   Web of Science ®Google Scholar
• Lindberg UB, Crona N, Stigendal L, Teger-Nilsson AC, Silfverstolpe G. A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters. Thromb Haemost. 1989;61(1):65–69.
   PubMed Web of Science ®Google Scholar
• Wiegratz I, Lee JH, Kutschera E, Winkler UH, Kuhl H. Effect of four oral contraceptives on hemostatic parameters. Contraception. 2004;70(2):97–106.
   PubMed Web of Science ®Google Scholar
• Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol. 1982;144(5):511–518.
   PubMed Web of Science ®Google Scholar
• Golbs S, Domhardt R, Radowicky S, Kaluzny Z, Wisser KH, Zimmermann T. Clinical findings with the oral contraceptive combination ethinylestradiol/dienogest in Poland. Methods Find Exp Clin Pharmacol. 2002;24(9):585–592.
   Google Scholar
• Golbs S, Domhardt R, Presl J, Ganev M, Wisser KH, Zimmermann T Clinical findings with the oral contraceptive combination ethinylestradiol/ dienogest in the Czech Republic. Methods Find Exp Clin Pharmacol. 2002;24(10):689–696.
   Google Scholar
• Zimmermann T, Dietrich H, Wisser KH, Hoffmann H. The efficacy and tolerability of Valette: a postmarketing surveillance study. Eur J Contracept Reprod Health Care. 1999;4(3):155–164.
   PubMed Web of Science ®Google Scholar
• Köhler G, Faustmann TA, Gerlinger C, Seitz C, Mueck AO. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynaecol Obstet. 2010;108(1):21–25. Erratum in: Int J Gynaecol Obstet. 2011;112(3):257.
   PubMed Web of Science ®Google Scholar
• Cosson M, Querleu D, Donnez J, et al. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertil Steril. 2002;77(4):684–692.
   PubMed Web of Science ®Google Scholar
• Schindler AE, Christensen B, Henkel A, Oettel M, Moore C. High-dose pilot study with the novel progestogen dienogestin patients with endometriosis. Gynecol Endocrinol. 2006;22(1):9–17.
   PubMed Web of Science ®Google Scholar
• Harada T, Momoeda M, Taketani Y, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis – a randomized, double-blind, multicenter, controlled trial. Fertil Steril. 2009;91(3):675–681.
   PubMed Web of Science ®Google Scholar
• Gerlinger C, Faustmann T, Hassal JJ, Seitz C. Treatment of endometriosis in different ethnic populations: a meta-analysis of two clinical trials. BMC Womens Health. 2012;12(1):9.
   Google Scholar
• Sasagawa S, Shimizu Y, Kami H, et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids. 2008;73(2):222–231.
   PubMed Web of Science ®Google Scholar
• Katayama H, Katayama T, Uematsu K, et al. Effect of dienogest administration on angiogenesis and hemodynamics in a rat endometrial autograft model. Hum Reprod. 2010;25(11):2851–2858.
   PubMed Web of Science ®Google Scholar
• Yamanaka K, Xu B, Suganuma I, et al. Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E2 production in human endometriotic stromal cells in spheroid culture. Fertil Steril. 2012;97(2):477–482.
   Web of Science ®Google Scholar
• Fruzzetti F, Tremollieres F, Bitzer J. An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest. Gynecol Endocrinol. 2012;28(5):400–408.
   PubMed Web of Science ®Google Scholar
• Mansour D, Verhoeven C, Sommer W, et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17ß-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care. Dec 2011 ;16(6):430–443.
   PubMed Web of Science ®Google Scholar
• Oettel M, Breitbarth H, Elger W. The pharmacological profile of dienogest. Eur J Contracept Reprod Health Care. 1999;4(Suppl 1):2–13.
   Google Scholar
• Hoffmann H, Moore C, Zimmermann H, et al. Approaches to the replacement of ethinylestradiol by natural 17beta-estradiol in combined oral contraceptives. Exp Toxicol Pathol. 1998;50(4–6):458–464.
   Google Scholar
• Endrikat J, Parke S, Trummer D, Schmidt W, Duijkers I, Klipping C. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception. 2008;78(3):218–225.
   PubMed Web of Science ®Google Scholar
• Timmer CJ, Geurts TB. Bioequivalence assessment of three different estradiol formulations in postmenopausal women in an open, randomized, single-dose, 3-way cross-over study. Eur J Drug Metab Pharma- cokinet. 1999;24(1):47–53.
   Web of Science ®Google Scholar
• Palacios S, Wildt L, Parke S, Machlitt A, Römer T, Bitzer J. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial. Eur J Obstet Gynecol Reprod Biol. 2010;149(1):57–62.
   PubMed Web of Science ®Google Scholar
• Kiley JW, Shulman LP. Estradiol valerate and dienogest: a new approach to oral contraception. Int J Womens Health. 2011;3:281–286.
   PubMedGoogle Scholar
• Helgason S. Estrogen replacement therapy after the menopause. Estrogenicity and metabolic effects. Acta Obstet Gynecol Scand Suppl. 1982;107:1–29.
   PubMedGoogle Scholar
• Kuhnz W, Gansau C, Mahler M. Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17 beta-estradiol. Arzneimittelforschung. 1993;43(9):966–973.
   PubMed Web of Science ®Google Scholar
• Moore C, Feichtinger W, Klinger G, et al. Clinical findings with dienogest-containing oral contraceptive Valette. Drugs Today (Barc). 1999;35(Suppl C):53–69.
   Google Scholar
• Foster RH, Wilde MI. Dienogest. Drugs. 1998;56(5):825–833; discussion 834–835.
   PubMed Web of Science ®Google Scholar
• Ruan X, Seeger H, Mueck AO. The pharmacology of dienogest. Maturitas. 2012;71(4):337–344.
   PubMed Web of Science ®Google Scholar
• Rabe T, Kowald A, Ortmann J, Rehberger-Schneider S. Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol. 2000;14(4):223–230.
   PubMed Web of Science ®Google Scholar
• Oettel M, Carol W, Gräser T, et al. Effect of ethinyl estradiol-dienogest combination on serum androgen concentrations. Zentralbl Gynakol. 1997;119(12):597–606.
   PubMedGoogle Scholar
• Kuhl H. Effects of progestogens on haemostasis. Maturitas. 1996;24(1–2):1–19.
   Web of Science ®Google Scholar
• Dü sterberg B, Nishino Y. Pharmacokinetic and pharmacological feature s of oestradiol valerate. Maturitas. 1982;4(4):315–324.
   Web of Science ®Google Scholar
• Longcope C, Williams KI. The metabolism of estrogens in normal women after pulse injections of 3H-estradiol and 3H-estrone. J Clin Endocrinol Metab. 1974;38(4):602–607.
   Web of Science ®Google Scholar
• Zeun S, Lu M, Uddin A, Zeiler B, Morrison D, Blode H. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care. 2009;14(3):221–232.
   PubMed Web of Science ®Google Scholar
• Lu M, Uddin A, Foegh M, Zeun S. Pharmacokinetics and pharmacodynamics of a new four-phasic estradiol valerate and dienogest oral contraceptive. Obstet Gynecol. 2007;109:61S.
   Web of Science ®Google Scholar
• Guida M, Bifulco G, Di Spiezio, et al. Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill. Int J Womens Health. 24 2010;2:279–290.
   PubMedGoogle Scholar
• Hoy SM, Scott LJ. Estradiol valerate/dienogest: in oral contraception. Drugs. 2009;69(12):1635–1646.
   Web of Science ®Google Scholar
• Kuhl H. Comparative pharmacology of newer progestogens. Drugs. 1996;51(2):188–215.
   PubMed Web of Science ®Google Scholar
• Oettel M, Carol W, Elger W, et al. A 19-norprogestin without a 17a-ethinyl group. II. Dienogest from a pharmacodynamic point of view. Drugs. 1995;31:517–536.
   Google Scholar
• US Food and Drug Administration. FDA labeling for estradiol valerate/ dienogest. Available from www.accessdata.fda.gov/drugsaffda_docs/label/2012/0222525001/61.pdf. Accessed November 23, 2012.
   Google Scholar
• Mansour D, Inki P, Gemzell-Danielsson K. Efficacy of contraceptive methods: a review of the literature. Eur J Contracept Reprod Health Care. Dec 2010;15 Suppl 2:S19–S31.
   Google Scholar
• Blode H, Zeun S, Parke S, et al. Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women. Contraception. 2012;86(4):337–344.
   PubMed Web of Science ®Google Scholar
• Mansour D. Qlaira: a ‘natural’ change of direction. J Fam Plann Reprod Health Care. 2009;35(3):139–142.
   Google Scholar
• Nelson A, Sampson-Landers C, Parke, et al. Efficacy of estradiol val- erate/dienogest oral contraceptive: results of 3 large studies in North America and Europe. Proceedings of the American College of Obstetricians and Gynecologists 57th Annual Clinical Meeting: May 2–6, 2009; Chicago, Illinois.
   Google Scholar
• Ahrendt HJ, Makalova D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/ dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009;80(5):436–444.
   PubMed Web of Science ®Google Scholar
• Hallberg L, Högdahl AM, Nilsson L, Rybo G. Menstrual blood loss – a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand. 1966;45(3):320–351.
   PubMed Web of Science ®Google Scholar
• Cole SK, Billewicz WZ, Thomson AM. Sources of variation in menstrual blood loss. J Obstet Gynaecol Br Commonw. 1971;78(10):933–939.
   Google Scholar
• Wyatt KM, Dimmock PW, Walker TJ, O’Brien PM. Determination of total menstrual blood loss. Fertil Steril 2001;76(1):125–131.
   PubMed Web of Science ®Google Scholar
• Côté I, Jacobs P, Cumming D. Work loss associated with increased menstrual loss in the United States. Obstet Gynecol. 2002;100(4):683–687.
   PubMed Web of Science ®Google Scholar
• Miller L, Verhoeven CH, Hout J. Extended regimens of the contraceptive vaginal ring: a randomized trial. Obstet Gynecol. 2005;106(3):473–482.
   PubMed Web of Science ®Google Scholar
• Jensen JT, Lefebvre P, Laliberté F, et al. Cost burden and treatment patterns associated with management of heavy menstrual bleeding. J Womens Health (Larchmt). 2012;21(5):539–547.
   Web of Science ®Google Scholar
• Fraser IS, Parke S, Mellinger U, Machlitt A, Serrani M, Jensen J. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care. 2011;16(4):258–269.
   PubMed Web of Science ®Google Scholar
• Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116(4):865–875.
   PubMed Web of Science ®Google Scholar
• Endrikat J, Shapiro H, Lukkari-Lax E, Kunz M, Schmidt W, Fortier M. A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Can. 2009;31(4):340–347.
   PubMedGoogle Scholar
• Shaaban MM, Zakherah MS, El-Nashar SA, Sayed GH. Levonorge strel- releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception. 2011;83(1):48–54. Erratum in: Contraception. 2011;84(1):112.
   Web of Science ®Google Scholar
• Bifulco G, Sardo AD, De Rosa N, Greco E, et al. The use of an oral contraceptive containing estradiol valerate and dienogest before office operative hysteroscopy: a feasibility study. Gynecol Endocrinol. 2012. [Epub ahead of print.]
   Web of Science ®Google Scholar
• Helgason S. Estrogen replacement therapy after the menopause. Estrogenicity and metabolic effects. Acta Obstet Gynecol Scand Suppl. 1982;107:1–29.
   PubMedGoogle Scholar
• Klipping C, Duijkers I, Parke S, Mellinger U, Serrani M, Junge W Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Drugs R D. 2011;11(2):159–170.
   PubMedGoogle Scholar
• Junge W, Mellinger U, Parke S, Serrani M. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig. 2011;31(8):573–584.
   PubMed Web of Science ®Google Scholar
• Parke S, Junge W, Mellinger U, Duijkers I, Klipping C. Comparative effects of four-phasic regime of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel on haemostatic parameters. Proceedings of the 24th Annual Meeting of the ESHRE; July 7–9, 2008; Barcelona, Spain.
   Google Scholar
• Borgelt LM, Martell CW. Estradiol valerate/dienogest: a novel combined oral contraceptive. Clin Ther. Jan 2012;34(1):37–55.
   Web of Science ®Google Scholar
• Mueck AO, Seeger H, Lüdtke R, Gräser T, Wallwiener D. Effect on biochemical vasoactive markers during postmenopausal hormone replacement therapy: estradiol versus estradiol/dienogest. Maturitas. May 30, 2001;38(3):305–313.
   Web of Science ®Google Scholar
• Wiegratz I, Kutschera E, Lee JH, et al. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception. Jan 2003;67(1):25–32.
   PubMed Web of Science ®Google Scholar
• Bitzer J, Parke S, Roemer T, Serrani M. Endometrial safety of an oral contraceptive containing estradiol valerate and dienogest. Int J Womens Health. 2011;18(3):127–132.
   Google Scholar
• Huib AAM Van Vliet, Marjolein Raps, Laureen M Lopez, Frans M Helmerhorst. Quadriphasic versus monophasic oral contraceptives for contraception. Cochran Database of Systematic Reviews. 2011, Issue 11 Art no:CD009038.
   Web of Science ®Google Scholar
• Wasiak R, Filonenko A, Vanness DJ, et al. Impact of estradiol-valerate/ dienogest on work productivity and activities of daily living in European and Australian women with heavy menstrual bleeding. Int J Womens Health. 2012;4:271–278.
   PubMedGoogle Scholar
• Nappi RE, Davis SR, Parke S, Mellinger U, Serrani M. Effects of estradiol valerate/dienogest compared with ethinyl estradiol/levonorgestrel on libido. Endocr Re. 2011;31(03 Meeting abstract):P1–P315.
   Google Scholar
• Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA. 2005;294(1):91–96.
   PubMed Web of Science ®Google Scholar
• Nappi RE. Association of E2V/DNG as contraceptive choice for a better quality of life of women. Minerva Ginecol. 2012;64(1):41–52.
   PubMedGoogle Scholar
• Caruso S, Agnello C, Romano M, et al. Preliminary study on the effect of four-phasic estradiol valerate and dienogest (E2V/DNG) oral contraceptive on the quality of sexual life. J Sex Med. 2011;8(10):2841–2850.
   PubMed Web of Science ®Google Scholar
• Van Vliet HA, Raps M, Lopez LM, Helmerhorst FM. Quadriphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev. 2011;11:CD009038.
   Web of Science ®Google Scholar
• Whalen KL, Rose R. Estradiol valerate/dienogest: a novel oral contraceptive. Ann Pharmacother. 2011;45(10):1256–1261.
   Web of Science ®Google Scholar